× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Background

What do we already know about this topic?

  • Atopic dermatitis (AD) is the most common form of eczema – affecting up to 25% of children and 10% of adults.1
  • Advances in understanding of the underlying molecular basis of the disease are leading to new therapies that target specific inflammatory pathways.1
  • Lebrikizumab is a monoclonal antibody with selectivity for IL-13.

How was this study conducted?

  • This was a double-blind, placebo-controlled, dose-ranging Phase 2b trial.
  • 280 AD patients were randomized 3:3:3:2 to received lebrikizumab 125 mg Q4W, 250 mg Q4W, 250 mg Q2W, or placebo Q2W for 16 weeks.
  • Lebrikizumab patients also received a loading dose equivalent to twice the randomized dose at Week 0 for the first two groups, and at Weeks 0 and 2 for the third group.
  • The primary endpoint was EASI (Eczema Area and Severity Index) change at Week 16; secondary endpoints evaluated the impact of lebrikizumab on patient-reported outcomes including quality of life, pruritus, and sleep.